News By Tag
News By Location
CHI to Host the 3rd Annual Companion Diagnostics Conference, Aug. 22-23, 2012, Washington, DC
Hear Diagnostics Perspectives on Personalized Medicine and Companion Tests. This conference is part of the Next Generation Dx Summit: Moving Assays to the Clinic.
The conference will cover some of the most important issues, including:
- Solutions for successful partnership with pharmaceutical companies
- Scientific advances in companion testing
- Reimbursement of companion testing
- Business models for pharma-diagnostics partnership
- Internal diagnostics and pharmaceutical partnership
Plenary Keynote Session:
Regulation of LDTs and RUOs
Alberto Gutierrez, Ph.D., Deputy Director, Office of in vitro Diagnostic Device Evaluation and Safety, Food & Drug Administration
Moderated by: Franklin R. Cockerill, III, M.D., Ann and Leo Markin Professor of Microbiology & Medicine; Chair, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine; President and CEO, Mayo Medical Laboratories and Mayo Collaborative Services, Inc.
Position of IVDs on Regulatory Issues
Alan Mertz, President, American Clinical Laboratory Association (ACLA)
Andrew C. Fish, Executive Director, AdvaMedDx
Distinguished Speaker Faculty:
Peter Collins, Ph.D., Vice President & Head, Diagnostics, GlaxoSmithKline Biologicals
Philip D. Cotter, Ph.D., F.A.C.M.G., Co-Founder, ResearchDx, LLC
Bruce H. Davis, M.D., President & Founder, Trillium Diagnostics, LLC
David C. Duffy, Ph.D., Vice President, Research, Quanterix Corporation
Gavin Erickson, Principal Consultant, GfK Bridgehead
Joseph V. Ferrara, President, Boston Healthcare
Matthew J. Hawryluk, Ph.D., Director, Business Development , Foundation Medicine, Inc.
Elaine K. Jeter, M.D., Medical Director, Palmetto GBA
Walter Koch, Ph.D., Vice President & Head, Global Research, Roche Molecular Systems
Tara Kochis, President, Slone Partners
Rainer Metzger, Ph.D., Vice President, Pharma Partnerships, Leica Biosytems
Richard A. Montagna, Ph.D., Senior Vice President, Scientific Affairs, RHEONIX, Inc.
Michael Nohaile, Ph.D., Global Head, Novartis Molecular Diagnostics
Richard K. Schatzberg, President and CEO, Generation Health
Catherine A. Schnabel, Ph.D., Senior Director, Medical & Scientific Affairs, bioTheranostics, Inc.
Cecilia Schott, Ph.D., M.B.A., Business Development Director, Personalized Healthcare, AstraZeneca
Premal Shah, Ph.D., Director, Business Development, Genomic Health, Inc.
Charles (Buck) Strom, M.D., Ph.D., Senior Medical Director, Genetics, Quest Diagnostics Nichols Institute
Patrick F. Terry, Principal, Pricing & Market Access Practice, Scientia Advisors
Speaker to be Announced, Myriad RBM
Sheila D. Walcoff, Esq., Founding Principal, Goldbug Strategies LLC and Counsel for the Coalition for 21st Century Medicine
As part of the Next Generation Dx Summit (Enabling Point-of-Care Diagnostics, Emerging Molecular Markers of Cancer, Molecular Diagnostics for Infectious Disease, Companion Diagnostics, Commercialization of Molecular Diagnostics, Mass Spec for the Clinic), this event will bring together all of the major players in the evolving areas of diagnostics.
Those that register by June 1 will save up to $350.
To register and view the full agenda, visit http://www.NextGenerationDx.com/
To inquire about sponsorship/
Writers and editors are invited to attend. To request a press pass, email email@example.com.
About Cambridge Healthtech Institute (www.chicorporate.com)
CHI is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and CHI’s Media Group, which includes news websites and e-newsletters including Bio-IT World and eCliniqua. Founded in 1992, CHI strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments.
Cambridge Healthtech Institute